Cancer vaccine for dogs shows potential

Cancer, a prevalent ailment in dogs, especially among larger and older breeds, parallels its occurrence in humans. However, while humans have

In a groundbreaking study conducted at Yale University, scientists have adapted existing human cancer treatments to develop a novel approach beneficial for both human and canine patients, capitalizing on shared characteristics of certain cancers across species. Monoclonal antibodies, a promising treatment modality, target proteins EGFR and HER2, which are often overexpressed in cancers such as colorectal and breast cancer, through

Despite the effectiveness of

Following the identification of a promising compound, researchers conducted extensive testing in mouse models before progressing to trials involving dogs. The results were remarkable, with the treatment exhibiting significant success in binding to tumors and disrupting critical pathways essential for tumor growth.

According to the researchers, their canine cancer vaccine has substantially improved the 12-month survival rate for dogs diagnosed with certain types of cancer. For instance, dogs afflicted with osteosarcoma, a bone cancer, typically have a 35% chance of surviving one year post-diagnosis with conventional treatments. However, the introduction of the cancer vaccine has elevated this survival rate to an impressive 60%.

VOCAB 1/5

an array of treatment options

một loạt các lựa chọn điều trị

radiation and chemotherapy

xạ trị và hóa trị

protein infusions

truyền protein

monoclonal

đơn dòng

polyclonal

đa dòng